AIM: To characterize quantitatively the relationship between ABT-102, a potent and selective TRPV1 antagonist, exposure and its effects on body temperature in humans using a population pharmacokinetic/pharmacodynamic modelling approach. METHODS:Serial pharmacokinetic and body temperature (oral or core) measurements from three double-blind, randomized, placebo-controlled studies [single dose (2, 6, 18, 30 and 40 mg, solution formulation), multiple dose (2, 4 and 8 mg twice daily for 7 days, solution formulation) and multiple-dose (1, 2 and 4 mg twice daily for 7 days, solid dispersion formulation)] were analyzed. NONMEM was used for model development and the model building steps were guided by pre-specified diagnostic and statistical criteria. The final model was qualified using non-parametric bootstrap and visual predictive check. RESULTS: The developed body temperature model included additive components of baseline, circadian rhythm (cosine function of time) and ABT-102 effect (Emax function of plasma concentration) with tolerance development (decrease in ABT-102 Emax over time). Type of body temperature measurement (oral vs. core) was included as a fixed effect on baseline, amplitude of circadian rhythm and residual error. The model estimates (95% bootstrap confidence interval) were: baseline oral body temperature, 36.3 (36.3, 36.4)°C; baseline core body temperature, 37.0 (37.0, 37.1)°C; oral circadian amplitude, 0.25 (0.22, 0.28)°C; core circadian amplitude, 0.31 (0.28, 0.34)°C; circadian phase shift, 7.6 (7.3, 7.9) h; ABT-102 Emax , 2.2 (1.9, 2.7)°C; ABT-102 EC50 , 20 (15, 28) ng ml(-1) ; tolerance T50 , 28 (20, 43) h. CONCLUSIONS: At exposures predicted to exert analgesic activity in humans, the effect of ABT-102 on body temperature is estimated to be 0.6 to 0.8°C. This effect attenuates within 2 to 3 days of dosing.
RCT Entities:
AIM: To characterize quantitatively the relationship between ABT-102, a potent and selective TRPV1 antagonist, exposure and its effects on body temperature in humans using a population pharmacokinetic/pharmacodynamic modelling approach. METHODS: Serial pharmacokinetic and body temperature (oral or core) measurements from three double-blind, randomized, placebo-controlled studies [single dose (2, 6, 18, 30 and 40 mg, solution formulation), multiple dose (2, 4 and 8 mg twice daily for 7 days, solution formulation) and multiple-dose (1, 2 and 4 mg twice daily for 7 days, solid dispersion formulation)] were analyzed. NONMEM was used for model development and the model building steps were guided by pre-specified diagnostic and statistical criteria. The final model was qualified using non-parametric bootstrap and visual predictive check. RESULTS: The developed body temperature model included additive components of baseline, circadian rhythm (cosine function of time) and ABT-102 effect (Emax function of plasma concentration) with tolerance development (decrease in ABT-102 Emax over time). Type of body temperature measurement (oral vs. core) was included as a fixed effect on baseline, amplitude of circadian rhythm and residual error. The model estimates (95% bootstrap confidence interval) were: baseline oral body temperature, 36.3 (36.3, 36.4)°C; baseline core body temperature, 37.0 (37.0, 37.1)°C; oral circadian amplitude, 0.25 (0.22, 0.28)°C; core circadian amplitude, 0.31 (0.28, 0.34)°C; circadian phase shift, 7.6 (7.3, 7.9) h; ABT-102 Emax , 2.2 (1.9, 2.7)°C; ABT-102 EC50 , 20 (15, 28) ng ml(-1) ; tolerance T50 , 28 (20, 43) h. CONCLUSIONS: At exposures predicted to exert analgesic activity in humans, the effect of ABT-102 on body temperature is estimated to be 0.6 to 0.8°C. This effect attenuates within 2 to 3 days of dosing.
Authors: Klaus Schaffler; Peter Reeh; W Rachel Duan; Andrea E Best; Ahmed A Othman; Connie R Faltynek; Charles Locke; Wolfram Nothaft Journal: Br J Clin Pharmacol Date: 2013-02 Impact factor: 4.335
Authors: H H Chuang ; E D Prescott; H Kong; S Shields; S E Jordt; A I Basbaum; M V Chao; D Julius Journal: Nature Date: 2001-06-21 Impact factor: 49.962
Authors: D Smart; M J Gunthorpe; J C Jerman; S Nasir; J Gray; A I Muir; J K Chambers; A D Randall; J B Davis Journal: Br J Pharmacol Date: 2000-01 Impact factor: 8.739
Authors: Susan M Huang; Tiziana Bisogno; Marcello Trevisani; Abdulmonem Al-Hayani; Luciano De Petrocellis; Filomena Fezza; Michele Tognetto; Timothy J Petros; Jocelyn F Krey; Constance J Chu; Jeffrey D Miller; Stephen N Davies; Pierangelo Geppetti; J Michael Walker; Vincenzo Di Marzo Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205
Authors: Jonathan Z Long; Alexander M Roche; Charles A Berdan; Sharon M Louie; Amanda J Roberts; Katrin J Svensson; Florence Y Dou; Leslie A Bateman; Amir I Mina; Zhaoming Deng; Mark P Jedrychowski; Hua Lin; Theodore M Kamenecka; John M Asara; Patrick R Griffin; Alexander S Banks; Daniel K Nomura; Bruce M Spiegelman Journal: Proc Natl Acad Sci U S A Date: 2018-07-02 Impact factor: 11.205
Authors: A Garami; E Pakai; H A McDonald; R M Reilly; A Gomtsyan; J J Corrigan; E Pinter; D X D Zhu; S G Lehto; N R Gavva; P R Kym; A A Romanovsky Journal: Acta Physiol (Oxf) Date: 2018-02-16 Impact factor: 6.311
Authors: Prasarn Manitpisitkul; Michael Brandt; Christopher M Flores; Velga Kenigs; John A Moyer; Gary Romano; Kevin Shalayda; Arthur J Mayorga Journal: Pain Rep Date: 2016-10-30